Zituvimet Xr Tablet, Film Coated, Extended Release
Product Images NDC 70710-1804

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zituvimet Xr (NDC 70710-1804). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (98507577 C0c5 453d A80c 9e106b7f667e 01)

Chemical structure of sitagliptin, one of the active ingredients in ZITUVIMET XR (sitagliptin and metformin hydrochloride). The diagram shows the molecular arrangement including trifluoromethyl and amino groups on the sitagliptin molecule.*

FDA Label Image

Image (98507577 C0c5 453d A80c 9e106b7f667e 02)

Chemical structure of sitagliptin and metformin hydrochloride shown as a molecular diagram indicating the arrangement of atoms, including functional groups and hydrochloride (HCl) salt form.*

FDA Label Image

Image (98507577 C0c5 453d A80c 9e106b7f667e 03)

A line graph showing least squares mean change from baseline over 24 weeks for six groups: placebo, sitagliptin 100 mg once daily, metformin immediate-release 500 mg twice daily, metformin immediate-release 1000 mg twice daily, sitagliptin 50 mg twice daily plus metformin immediate-release 500 mg twice daily, and sitagliptin 50 mg twice daily plus metformin immediate-release 1000 mg twice daily. The y-axis represents LS mean change from baseline, and the x-axis represents weeks from 0 to 24.*

FDA Label Image

Image (98507577 C0c5 453d A80c 9e106b7f667e 04)

A line graph comparing the least squares mean change from baseline over 52 weeks for Sitagliptin 100 mg and Glipizide. The x-axis represents weeks from 0 to 52, and the y-axis shows the change from baseline. Both lines show a downward trend followed by a gradual increase.*

FDA Label Image

Zituvimet Xr, 50mg/500mg-image 01 (98507577 C0c5 453d A80c 9e106b7f667e 05)

Label for ZITUVIMET XR 50 mg/500 mg film-coated extended-release tablets containing sitagliptin and metformin hydrochloride. The label indicates oral use, a package size of 60 tablets, and provides pharmacist instructions and storage guidelines. The product is labeled by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Zituvimet Xr, 50mg/1,000mg-image 01 (98507577 C0c5 453d A80c 9e106b7f667e 06)

The label for ZITUVIMET XR (sitagliptin and metformin HCl) extended-release tablets, oral use, strength 50 mg/1,000 mg. The label shows a 60-tablet count package by Zydus Pharmaceuticals USA Inc. It includes the NDC 70710-1805-6, pharmacy dispensing info, usage instructions, and storage guidelines.*

FDA Label Image

Zituvimet Xr, 100mg/1,000mg-image 01 (98507577 C0c5 453d A80c 9e106b7f667e 07)

Label for ZITUVIMET XR extended-release tablets containing sitagliptin 100 mg and metformin hydrochloride 1000 mg. The orally administered film-coated tablets come in a 30-count package. The label includes storage and handling instructions, dispensing information for pharmacists, and manufacturer details for Zydus Pharmaceuticals USA Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.